Clinical trials: SGLT 2 Inhibitors
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Type2diabetes
Effect of SGLT-2 Inhibitors in Patients With T2DM and Moderate to Severe Liver Fibrosis
This retrospective study will be of 12 months duration where 40 T2DM patients coming to FORTIS C-DOC hospital in OPD with F3 fibrosis will be included in the study.
- Trial name
- NCT05943899
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort Study
This is a prospective single-center cohort study conducted at The First Affiliated Hospital of Xinjiang Medical University, aiming to enroll 400 patients with chronic heart failure (including HFrEF, HFmrEF, HFpEF) and 200 healthy…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Trial name
- HF-MultiOmics (NCT07355088)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xinjiang Medical University
Diabetes Mellitus, Type 2
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of…
- Trial name
- NCT01248364
- Testing
- BI 10773
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Polycystic Ovary Syndrome, Obesity
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin…
- Trial name
- NCT02635386
- Testing
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Woman's
Diabetes Mellitus, Type 2
Genetics of Response to Canagliflozin
Five daily doses of canagliflozin (300 mg) will be administered to healthy volunteers. Pharmacodynamic responses to canagliflozin will be assessed both at 2 days and 6 days after administration of the first dose of canagliflozin.
- Trial name
- NCT02891954
- Testing
- Canagliflozin
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
End Stage Renal Disease
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).
A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)
- Trial name
- NCT03713190
- Testing
- Empagliflozin
- Where
- Italy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Inappropriate ADH Syndrome
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.
- Trial name
- DIVE (NCT02729766)
- Testing
- Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Type 2 Diabetes
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days.
- Trial name
- SINGLED (NCT04219124)
- Testing
- IMP oral tablet
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Type 2 Diabetes Mellitus
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
The main pathogenesis of type 2 diabetes mellitus is insulin resistance and insufficient secretion of insulin by pancreatic beta cells.
- Trial name
- NCT04014192
- Testing
- Dapagliflozin, Empagliflozin, Canagliflozin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Large Vessel Vasculitis, Giant Cell Arteritis (GCA)
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Large vessel vasculitis (LVV) is a disease that causes damage to blood vessels. This damage to blood vessels can increase the risk of patients with LVV developing cardiovascular disease, including heart attacks and strokes.
- Conditions
- Large Vessel Vasculitis, Giant Cell Arteritis (GCA), Takayasu Arteritis
- Trial name
- DERAIL-LVV (NCT06887062)
- Testing
- Bosentan and dapagliflozin
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Inflammation
Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation
The research aims to understand how a specific type of medication called Sodium-glucose co-transporter 2 (SGLT2) inhibitors affect cardiorenal inflammation.
- Trial name
- EFSII (NCT06812429)
- Testing
- Dapagliflozin (DAPA)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Ketones, Metabolism
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
The purpose of this study is to help us better understand how plasma ketones respond to a low-carb diet when combined with an SGLT2 inhibitor.
- Trial name
- CASINO (NCT05662865)
- Testing
- SGLT2 inhibitor, Controlled, Adaptive Study Diet
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
SGLT2 Inhibitors, Lower Urinary Track Symptoms
SGLT-2 Inhibitors and Lower Urinary Tract Symptoms
This prospective observational study aims to evaluate the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on lower urinary tract symptoms (LUTS) in patients with type 2 diabetes mellitus.
- Conditions
- SGLT2 Inhibitors, Lower Urinary Track Symptoms, Overactive Bladder
- Trial name
- NCT07716774
- Testing
- No Intervention: Observational Cohort
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Marmara University
Diabetic Ketoacidosis, Postoperative Care
Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users
The goal of this observational study is to determine the frequency of postoperative euglycemic diabetic ketoacidosis (EDKA) in patients receiving Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors.
- Trial name
- SGLT-2I (NCT07127406)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kocaeli City Hospital
Type 2 Diabetes Mellitus
Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers
The primary purpose of this trial is to assess the safety and tolerability of ISIS-SGLT2Rx when given at increasing single doses and to assess the safety and tolerability of the same doses when given multiple times.
- Trial name
- NCT00836225
- Testing
- ISIS 388626
- Where
- Netherlands
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Acute Kidney Injury, Percutaneous Coronary Intervention
Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury
To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the usual standard of care.
- Trial name
- DAPA-PCI-AKI (NCT05435235)
- Testing
- Dapagliflozin 10mg Tab
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Albert Einstein Healthcare Network
Anemia in CKD Patients
Effect of SGLT2 Inhibitors on Anemic CKD Patients
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its…
- Trial name
- NCT07334145
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University